The dose figures attached to this peptide almost all belong to a different molecule. Published human dosing describes AOD9604, a synthetic analogue of the C-terminal fragment of human growth hormone carrying an added N-terminal tyrosine, given orally to obese adults; the unmodified 176-191 sequence sold under the fragment name has never been through a controlled human dose-finding study. Neither compound is approved as a medicine in any major market, and material sold for the purpose is labelled for laboratory research rather than human use.
Every published human dose in this molecule class describes oral AOD9604 at 0.25 mg to 30 mg daily across twelve to twenty-four weeks, and no controlled human trial has administered the unmodified 176-191 fragment by injection at any dose.
Two studies carry the entire human dose record, and they point in different directions. Metabolic Pharmaceuticals ran a twelve-week Phase 2b dose-ranging study in roughly three hundred obese adults, then a larger twenty-four-week confirmatory study in roughly five hundred, both using once-daily oral AOD9604. The weight figures quoted most often come from sponsor-reported programme outcomes rather than from a peer-reviewed randomised efficacy publication, a distinction later reviewers have drawn explicitly.
| Criteria | Phase 2b (12 weeks) | Confirmatory study (24 weeks) |
|---|---|---|
| Daily oral dose arms | 1, 5, 10, 20, 30 mg | 0.25 mg to 1 mg |
| Randomised participants | ~300 | ~500 |
| Weight outcome | ~2.5 kg in lowest arm vs ~1 kg placebo | No separation from placebo |
| Dose-response | Flat or inverted across arms | Not established |
The published human dose record covers oral AOD9604 at 1 mg to 30 mg daily for twelve weeks and 0.25 mg to 1 mg daily for twenty-four weeks, with no injectable arm at any dose.
Nothing about the rodent dose selection was peculiar to this peptide; it followed the ordinary logic of metabolic pharmacology. What travels badly is the arithmetic that follows, since allometric conversion from a mouse milligram-per-kilogram dose yields a first-in-human starting estimate, not a regimen for anything.
The founding rodent studies dosed the fragment on a weight-normalised microgram-per-kilogram to low milligram-per-kilogram basis for fourteen to nineteen days by intraperitoneal injection or oral gavage, routes with no human clinical equivalent.
Route was the commercial thesis here, not an incidental detail. The developer pursued an oral preparation on the reasoning that a sixteen-residue fragment acting on adipocyte lipid metabolism might tolerate the low absorption of oral peptide delivery and still register a metabolic effect, which is why the human arms are stated in milligrams per day rather than micrograms per injection.
Oral administration is the only route with controlled human dosing data behind it, and subcutaneous injection, the route most associated with this peptide, appears nowhere in the published human trial record.
A sixteen-amino-acid peptide with no stabilising modification is short-lived in plasma, with reported circulating half-lives after parenteral administration falling in minutes rather than hours. On a naive reading that argues for frequent or continuous delivery, yet the clinical program dosed once daily throughout, on a pharmacodynamic rather than a pharmacokinetic rationale.
Once-daily dosing in the clinical program rested on a pharmacodynamic argument rather than on plasma exposure, since the peptide's reported half-life after parenteral administration is measured in minutes.
The tolerability record is reassuring about exactly one thing: oral AOD9604 at the doses and durations tested. A published safety review consolidating exposure across the clinical program reported adverse event profiles broadly comparable to placebo, dominated by mild non-specific complaints such as headache, nausea and dizziness. Whole categories of exposure were never examined at all.
A benign oral tolerability profile recorded at up to 30 mg daily over twelve weeks carries no information about repeated subcutaneous injection of research-grade material, where injection site reactions, sterility, purity and immunogenicity remain unexamined.
Set the two side by side and they barely overlap. The convention on supplier pages and discussion boards differs from the trial record on the molecule, the route, the unit scale by three orders of magnitude, and on whether the schedule was ever tested against a control at all. The site-specific injection claim has no published finding behind it, since the animal work measured systemic adiposity and enzyme activity rather than where fat was mobilised from.
| Dimension | Circulating convention | Published trial record |
|---|---|---|
| Molecule | Unmodified 176-191 sequence | AOD9604 analogue |
| Route | Subcutaneous injection | Oral |
| Amount | 250 to 500 mcg, once or twice daily | 1 mg to 30 mg once daily |
| Schedule | Cycles of weeks to months, often fasted | 12 or 24 weeks of continuous dosing |
| Control arm | None | Placebo-controlled |
The 250 to 500 microgram subcutaneous convention traces back to product listings and forum posts citing one another rather than to any dose-finding study, and sits three orders of magnitude away from the trial record in unit scale.
No regulator in a major market has approved this peptide or its analogue as a medicine for any indication, and that single fact governs every other constraint. The rules that do apply arrive from three separate directions: supplement and compounding regulation, anti-doping policy, and national import and prescription law.
The compound is prohibited at all times under the World Anti-Doping Agency list, unapproved as a medicine in every major market, and sold labelled for laboratory research rather than human consumption.
Laboratory handling practice answers one problem: a small peptide is fragile, and the delivered amount is only as good as the material and the technique. The gap with the clinical program is widest here, because the trial product was manufactured to pharmaceutical quality standards with documented content uniformity, while research-grade material in this class carries purity and dose consistency that nobody independently assures.
Labelled content and delivered content are separate quantities for research-grade peptide material, since purity, sterility and dose consistency are not independently assured and dilute peptide solutions lose measurable amounts to container surfaces.
After the obesity indication stalled, interest moved toward musculoskeletal tissue, and the dosing vocabulary changed with it. Dose in that work is stated as an amount per joint per injection on an intermittent schedule, a figure that is not convertible into a daily systemic amount and is regularly quoted as though it were.
Non-obesity work on the analogue remains preclinical, dosed per joint per injection in animal cartilage and osteoarthritis models, and has produced no validated human dosing regimen for any indication.
The most consequential gap is not a missing number but a missing relationship. A dose-ranging study whose lowest arm outperformed arms up to thirty times larger has not demonstrated a dose-response, and a larger confirmatory trial showing no separation from placebo makes noise the ordinary reading of that original signal. Everything downstream inherits the uncertainty.
The dosing literature supports two narrow statements, that oral AOD9604 was reasonably tolerated at 1 mg to 30 mg daily for twelve weeks without a reproducible weight-loss effect, and that rodent studies at weight-normalised doses reduced fat mass without the metabolic disturbance full-length growth hormone produced.
Educational use only. This article describes what the published scientific and clinical literature reports about HGH Fragment 176-191. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
